title: Immunotherapy in acute myeloid leukemia.
abstract: Treatment of acute myeloid leukemia (AML) with current chemotherapy regimens is still disappointing, with overall survival rates of ≤ 40% at 5 years. It is now well established that AML cells can evade the immune system through multiple mechanisms, including the expression of the enzyme indoleamine 2,3 dioxygenase. Immunotherapeutic strategies, including both active, such as vaccination with leukemia-associated antigens, and passive, such as adoptive transfer of allogeneic natural killer cells, may overcome leukemia escape and lead to improved cure. Allogeneic hemopoeitic stem cell transplantation, the most effective treatment of AML, is the best known model of immunotherapy. Following transplant, recipient AML cells are eradicated by donor immune cells through the graft-versus-leukemia (GVL) effect. However, GVL is clinically associated with graft-versus-host disease, the major cause of mortality after transplant. GVL is mediated by donor T cells recognizing either leukemia-associated antigens or minor as well as major histocompatibility antigens. Several innovative strategies have been devised to generate leukemia reactive T cells so as to increase GVL responses with no or little graft-versus-host disease.
authors.affiliation: Department of Hematology & Oncological Sciences 'Seragnoli', University of Bologna, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Arpinati
authors.forename: Antonio
authors.initials: A
authors.lastname: Curti
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D020350:Graft vs Tumor Effect; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D016219:Immunotherapy, Adoptive / Q000379:methods*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation*; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000276:immunology / Q000628:therapy*; D019139:Tumor Escape
chemical_list: D000951:Antigens, Neoplasm; D006680:HLA Antigens; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase